2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172537
    Indolimine-214 3034091-87-4
    Indolimine-214 is a metabolite of M. morganii Indolimine-214 increases the level of γH2AX in HeLa cells. Indolimine-214 can be used in the study of inflammatory bowel disease (IBD) and colorectal cancer (CRC).
    Indolimine-214
  • HY-172540
    cyclo-Cannabigerol
    cyclo-Cannabigerol (cyclo-CBG) is the major metabolite of Cannabigerol generated by cytochrome P450. Cyclo-Cannabigerol has weak anti-inflammatory activity.
    cyclo-Cannabigerol
  • HY-172568
    (±)5(6)-EET Ethanolamide
    (±)5(6)-EET Ethanolamide is a metabolite of Anandamide (HY-10863) generated via oxidation by cytochrome P450 enzymes. (±)5(6)-EET Ethanolamide is also a selective cannabinoid receptor 2 (CB2) agonist. (±)5(6)-EET Ethanolamide has Ki values of 11.4 μM and 8.9 nM for human CB1 and CB2, respectively . (±)5(6)-EET Ethanolamide can be used in research on immunomodulation and neuroinflammation.
    (±)5(6)-EET Ethanolamide
  • HY-172594
    HPK1-IN-57 98%
    HPK1-IN-57 (Compound 10c) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 value of 0.09 nM. HPK1-IN-57 inhibits the activity of HPK1 kinase, hindering the phosphorylation of the downstream adaptor protein SLP76 (IC50 is 33.74 nM) and effectively stimulating the secretion of the T cell activation marker IL-2 (EC50 is 84.24 nM). HPK1-IN-57 is promising for research of tumor immunotherapy.
    HPK1-IN-57
  • HY-172596
    TYK2 activator-1 3087219-47-1 98%
    TYK2 activator-1 (16b) is a TYK2 activator with anEC50 of 1.78 μM. TYK2 activator-1 inhibits JAK2 and JAK3 with the IC50 values of 6.8 and 6.3 μM, respectively.
    TYK2 activator-1
  • HY-172598
    Keap1-Nrf2-IN-28 3075750-60-3 98%
    Keap1-Nrf2-IN-28 (SG16) is an orally active Keap1-Nrf2 inhibitor. Keap1-Nrf2-IN-28 shows antioxidant capability and induces the upregulation of Nrf2, HO-1, GCLM, and Akr1c1. Keap1-Nrf2-IN-28 attenuates APAP (HY-66005)-induced acute liver injury.
    Keap1-Nrf2-IN-28
  • HY-172600
    TRPC6 antagonist-1 98%
    TRPC6 antagonist-1 (X26) is a TRPC6 antagonist with IC50 values of 0.97 μM, 3.93 μM, 5.77 μM and 4.37 μM for TRPC6, TRPC3, TRPC5 and TRPC7, respectively. TRPC6 antagonist-1 inhibits TGF-β1-induced myofibroblast differentiation, and attenuates renal fibrosis.
    TRPC6 antagonist-1
  • HY-172608
    TNF-α-IN-24 3075686-66-4 98%
    TNF-α-IN-24 (Example 15) is a TNF-α inhibitor with an IC50 of 4.1 nM. TNF-α-IN-24 can be used in study of inflammatory and autoimmune disorders such as rheumatoid arthritis and Crohn’s disease.
    TNF-α-IN-24
  • HY-172619
    BS-153 1935692-54-8 98%
    BS-153 is a novel synthetic oxazolidinone agent with anti-inflammatory activities by blocking the activation of the NF-κB/PKCθ pathway. BS-153 inhibits the expression levels of iNOS and COX-2 and pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) on LPS-stimulated RAW264.7 cells.
    BS-153
  • HY-172620
    LIB3S0280 99.89%
    LIB3S0280 is a potent TBK1 inhibitor with an IC50 value of 493.9 nM. LIB3S0280 exhibits better anticancer effects in pancreatic cancer cell lines with high TBK1 expression. LIB3S0280 inhibits TBK1 downstream signaling pathways, including PI3K/AKT and NF-κB. LIB3S0280 induces G2/M arrest, apoptosis and cellular senescence. LIB3S0280 can be used for pancreatic ductal adenocarcinoma (PDAC) research.
    LIB3S0280
  • HY-172632
    Resolvin D3 methyl ester
    Resolvin D3 methyl ester is a methyl ester version of Resolvin D3 that may act as a lipophilic prodrug form which can alter its distribution and pharmacokinetic properties. Resolvin D3 is a potent immunoresolvent. Resolvin D3 can reduce neutrophil infiltration in vivo. Resolvin D3 can be produced in murine inflammatory exudates and human macrophages. Resolvin D3 can activate the human RvD1 and RvD5. Resolvin D3 is a potent enhancer of the uptake of apoptotic neutrophils by macrophages as well as a stimulator of IL-10.
    Resolvin D3 methyl ester
  • HY-172635
    Sphingosine-1-phosphate (d18:1(14Z))
    Sphingosine-1-phosphate (d18:1(14Z)) is an atypical sphingolipid that has a cis double bond at the 14-15 position. Sphingosine-1-phosphate is a critical regulator of various physiological and pathophysiological processes, such as cancer, atherosclerosis, diabetes and osteroporosis. Sphingosine-1-phosphate can be studied in research for inflammatory diseases, cancer and Alzheimer’s disease.
    Sphingosine-1-phosphate (d18:1(14Z))
  • HY-172653
    Sphingosine-1-phosphate (d18:1) alkyne
    Sphingosine-1-phosphate (d18:1) alkyne is an w-alkyne form of sphingosine-1-phosphate. Sphingosine-1-phosphate is a critical regulator of various physiological and pathophysiological processes, such as cancer, atherosclerosis, diabetes and osteroporosis. Sphingosine-1-phosphate can be studied in research for inflammatory diseases, cancer and Alzheimer’s disease.
    Sphingosine-1-phosphate (d18:1) alkyne
  • HY-172680
    DSPE-PEG1000-VIP 98%
    DSPE-PEG1000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG1000-VIP can be used for drug delivery.
    DSPE-PEG1000-VIP
  • HY-172681
    DSPE-PEG2000-VIP 98%
    DSPE-PEG2000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG2000-VIP can be used for drug delivery.
    DSPE-PEG2000-VIP
  • HY-172682
    DSPE-PEG5000-VIP 98%
    DSPE-PEG5000-VIP is a PEG compound which composed of DSPE and a vasoactive intestinal peptide (VIP). DSPE-PEG5000-VIP can be used for drug delivery.
    DSPE-PEG5000-VIP
  • HY-172695
    DSPE-PEG1000-WYRGRL 98%
    DSPE-PEG1000-WYRGRL is a PEG compound which composed of DSPE and a cartilage-targeting peptide (WYRGRL). WYRGRL is a collagen II-targeting peptide that can bind to collagen II α1. DSPE-PEG1000-WYRGRL can be used for drug delivery.
    DSPE-PEG1000-WYRGRL
  • HY-172697
    DSPE-PEG5000-WYRGRL 98%
    DSPE-PEG5000-WYRGRL is a PEG compound which composed of DSPE and a cartilage-targeting peptide (WYRGRL). WYRGRL is a collagen II-targeting peptide that can bind to collagen II α1. DSPE-PEG5000-WYRGRL can be used for drug delivery.
    DSPE-PEG5000-WYRGRL
  • HY-172776
    Phosphodiesterase-IN-3 3042880-01-0 98%
    Phosphodiesterase-IN-3 (Example 20) is a phosphodiesterase 4B inhibitor, with IC50s of <10 nM and 10-100 nM for PDE4B1 and PDE4D3, respectively. Phosphodiesterase-IN-3 has the potential for the research of idiopathic pulmonary fibrosis.
    Phosphodiesterase-IN-3
  • HY-172778
    HNW005 98%
    HNW005 is a dual inhibitor of NLRP3 inflammasome and urate transporter 1 (URAT1). It has a KD value of 204.6 nM and an IC50 of 1.7 μM for inhibiting NLRP3 inflammasome activation, and an IC50 of 6.4 μM for inhibiting uric acid transmembrane transport. When administered at a dose of 2 mg/kg in vivo, HNW005 can achieve a uric acid reduction rate of 64.8%. It can exert anti - inflammatory, analgesic, and uric acid - lowering activities by inhibiting the activation of NLRP3 inflammasome and uric acid transmembrane transport. HNW005 can be used in the research of gouty arthritis.
    HNW005
Cat. No. Product Name / Synonyms Application Reactivity